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Perspective

Sorting Reality from What We Think We Know About
Breast Cancer in Africa
Sulma I. Mohammed1*, Joe B. Harford2*
1 Department of Comparative Pathobiology and Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana, United States of America,
2 Center for Global Health, National Cancer Institute, Bethesda, Maryland, United States of America

Much attention has been paid to the
features of breast cancer in Africa and the
parallels between breast cancer in indigenous Africans and in African American
women, including a shift toward earlier
onset; a tendency toward poorer outcomes; and an increased likelihood for
the tumors to be negative for the estrogen
receptor (ER), the progesterone receptor
(PR), and/or the human epidermal growth
factor receptor-2 (HER2) [1,2]. One of the
more aggressive forms of breast cancer is
termed ‘‘triple negative,’’ i.e., ER2, PR2,
HER22 [3]. Patients with triple negative
breast cancer tend to be younger than
patients with other forms of the disease,
and at all ages, the triple negative subtype
is more common in women of African
descent than in the white women in the
United States [4–6].

Lack of Cancer Research in
Africa
A systematic review examining breast
cancer subtypes in Africa is published in
this week’s PLOS Medicine by Isabel
dos-Santos-Silva and colleagues [7]. A takehome message of the review article is that
caution should be exercised in stating what
we know (or think we know) about the
receptor status of breast cancers in Africa.
The paucity of breast cancer–relevant
research in Africa means that any generalization will be based on relatively few
studies of varying quality from relatively
few places on a very diverse continent. Of
54 studies from North Africa, approximately 80% of all the studies reviewed
were from Egypt or Tunisia. In subSaharan Africa (nearly 50 countries), two
countries (Nigeria and South Africa)
contributed more than half of the 26
studies. In addition to the limited geo-
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Linked Research Article
This Perspective discusses the following new study published in PLOS Medicine:
Eng A, McCormack V, dos-Santos-Silva I (2014) Receptor-Defined Subtypes of
Breast Cancer in Indigenous Populations in Africa: A Systematic Review and MetaAnalysis. PLoS Med 11(9): e1001720. doi:10.1371/journal.pmed.1001720
In a systematic review and meta-analysis, Isabel dos-Santos-Silva and colleagues
estimate the prevalence of receptor-defined subtypes of breast cancer in North
Africa and sub-Saharan Africa.

graphic representation, many studies involved fewer than 300 patients.

The Asymmetry of Positive and
Negative Test Results
dos-Santos-Silva and colleagues [7] note
that there has been a substantial increase
over time in the proportion of ER+ breast
cancers being reported. This increase
found in comparing studies prior to 2001
to those after 2007 is more likely a
reflection of an increased capability of
African pathology laboratories to conduct
the tests for receptor status reliably than a
true shift in tumor biology. This observation highlights a feature of receptor status
determination that is often ignored—
namely, that a positive result in a test
based on immunohistochemistry is inherently more reliable than a negative result
using the same test in the same laboratory.
If a sample is somehow mistreated or the
test is botched in some way, the test results
on even a receptor-positive specimen will

be scored as ‘‘negative.’’ In sub-Saharan
Africa, those studies employing archival
material (tissue blocks) were more likely
negative for ER and PR than those based
on prospectively analyzed specimens. Similarly, studies from North Africa using
formalin-fixed paraffin-embedded blocks
reported lower ER+ and PR+ proportions
than those using frozen tissue samples, and
almost all studies from sub-Saharan Africa
utilized formalin-fixed paraffin blocks.
Technical factors related to specimen
characteristics, including preparation and
storage, would tend to bias results asymmetrically toward receptor negativity and
lead to overestimates of receptor negativity
relative to the true underlying biology of
the tumors.
Routine testing for receptor status
remains uncommon in most of subSaharan Africa. When such tests are
attempted, potential issues that may lead
to poor results include overdilution of the
formalin to stretch the reagent and poor
control of timing and conditions of
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fixation, e.g., poor buffering of pH. In
some venues, tissue samples are actually
given to patients in formalin who keep the
specimens at home (sometimes for months,
with temperatures greater than 100uF)
until they can afford the cost of the
receptor status test(s). In some settings
where ER status is unknown and tamoxifen is available and affordable, all patients
with breast cancer are given tamoxifen
even though only ER+ patients would be
expected to benefit [8]. Health system
policy regarding cost and resource availability may also come into play. It is our
understanding, for example, that the
National Health Insurance System in
Ghana covers the cost of tamoxifen for
breast cancer patients but does not cover
the cost of the test for ER status.
Another very important point made by
dos-Santos-Silva and colleagues [7] is that
expressing receptor status in simple terms
of the proportion of breast cancers that are
ER2 may be of limited usefulness. Two
populations with identical incidence rates
of ER2 breast cancer may have different
proportions for this form of breast cancer
if total breast cancer rates differ in the two
populations. Proportions of certain forms
of breast cancer (e.g., inflammatory, triple
negative, or in males) are often cited as
being higher in Africa without acknowledging that these higher proportions are
actually being driven mathematically by
lower rates of other forms of breast cancer
rather than higher rates of the form in
question [9].

The Age Structure of the African
Population
The mean age for breast cancer in
Africa is undeniably younger, but one
must remember that the mean age for
almost anything in Africa is likely to be
younger, because Africa has by far the
youngest population of any continent on
the planet [10]. Given that age is the single
most substantive risk factor for most
cancers, including breast cancer, a younger population will have both lower overall
incidence of breast cancer and a lower
mean age of onset based simply on the
demographics of the population. This
point has been made previously in comparing the relatively younger population of
Egypt with that of the US [11], but all of
the principles of this comparison would
apply to the younger populations that exist
throughout Africa and, indeed, in other
younger populations, e.g., in Arab populations [12]. It should also be noted that
the median age of diagnosis of nonHispanic black women in California was
reported to be 7 years younger than that of
non-Hispanic white women covered by
the same cancer registry [9]. The likelihood of a US woman having a triple
negative tumor is highest in premenopausal black women [5]. In Africa, a much
larger fraction of the breast cancer cases
happens to be in premenopausal black
women, because they make up a much
larger fraction of the population there.
The question has been raised as to
whether Africans are more likely to be
diagnosed at a younger age because they

are triple negative or if they are more
likely to be triple negative because they are
younger [3]. It should also be noted that a
propensity toward negative receptor status
is by no means limited to Africans and
African American women. In a review of
data from the Surveillance, Epidemiology,
and End Results (SEER) Program, racial
or ethnic groups in the US that had
elevated risk of diagnosis with ER2/PR2
breast cancers relative to non-Hispanic
white women included Native Americans,
Filipinos, Chinese, Koreans, Vietnamese,
Indians/Pakistanis, Mexicans, South or
Central Americans, and Puerto Ricans
living in the US, in addition to African
Americans [13].
The systematic review of dos-SantosSilva and colleagues [7] serves to caution
caution against overstating what we know
(or think we know) about breast cancer
in Africa. The authors suggest that the
distribution of receptor-defined subtypes
of breast cancer in Africa may not be
dramatically different from that found
in Western populations, given the younger
age overall of the population in Africa.
We would concur with the authors that
much more research is needed to sort
what we believe to be true from the reality
of breast cancer in Africa.
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